<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the absence of a <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> phenotype, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients referred for genetic testing because of early-<z:hpo ids='HP_0003674'>onset</z:hpo> disease and/or a positive family history, typically undergo testing for molecular signs of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> in their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the absence of these signs, DNA testing for germline mutations associated with other known <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> syndromes is usually not performed </plain></SENT>
<SENT sid="2" pm="."><plain>However, a few studies in large series of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients suggest that in a small percentage of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases, bi-allelic MUTYH germline mutations can be found in the absence of the MUTYH-associated <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> phenotype </plain></SENT>
<SENT sid="3" pm="."><plain>This has not been studied in the Dutch population </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, we analyzed the MUTYH gene for mutations in 89 patients with microsatellite-low or stable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosed before the age of 40 years or otherwise meeting the Bethesda criteria, <z:hpo ids='HP_0000001'>all</z:hpo> of them without a <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> phenotype </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, we studied a series of 693 non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with 1-13 adenomatous colorectal <z:mpath ids='MPATH_491'>polyps</z:mpath> for the MUTYH hotspot mutations Y179C, G396D and P405L </plain></SENT>
<SENT sid="6" pm="."><plain>No bi-allelic MUTYH mutations were observed </plain></SENT>
<SENT sid="7" pm="."><plain>Our data suggest that the contribution of bi-allelic MUTYH mutations to the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in Dutch non-<z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> patients that meet clinical genetic referral criteria, and to the development of low number of colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> in non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, is likely to be low </plain></SENT>
</text></document>